Sovihep Tablets Trade Information
|Minimum Order Quantity||1.00||Unit of Measure||Piece/Pieces|
|Payment Terms||Paypal, Others||Delivery Time||7-15 Days|
|Packaging Details||Carton Boxes Packaging||Main Export Market(s)||Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Africa|
|Main Domestic Market||All India||Certifications||Certified Products.|
|Export Countries Details||Countries: Russsia, Ukrain, Korean, Ajbakistan, Kajistan, Poland, USA, India, Philipines & China|
Sovihep Tablets Description
Sovihep tablets should be used combination with ribavirin or in combination with pegylated interferon. We have been able to attain strong market goodwill as a trusted organization engaged in offering our clients Sovihep Sofosbuvir 400mg Tablets. These tablets are indicated in combination with other medical products for the treatment of chronic hepatitis C in adults. We source these tablets from the trusted and reliable vendors of the market. We offer these Sofosbuvir 400mg Tablets at reasonable prices to clients.
- Taken orally
- Consumed with or without food
- Low indication of side effects
Buy Sovihep from India Exporters, Suppliers & Distributors
Zydus Sofosbuvir Tablets SoviHep
SoviHep tablets are administered orally. Each tablet contains 400 mg.
INDICATIONS AND USAGE
SoviHep is indicated in combination with other medical products for the treatment of chronic hepatitis C (CHC) in adults.
DOSAGES AND ADMINISTRATION
Recommended Dose in adults
The recommended dose of tablets is one 400 mg tablet, taken orally, once daily with or without food SoviHep should be used combination with ribavirin or in combination with pegylated interferon and ribavirin for the treatment of CHC in adults.The recommended regimen and treatment duration for the combination therapy is provided in following table.
Recommended Regimens and Treatments Duration for SoviHep Combination Therapy in HCV Mono-infected and HCH/HIV-1 Co-infected Patients
|Patients with genotype 1 of 4 CHC||SoviHep + peginsterferon alfaa +ribavirinb||12 weeks|
|Patients with genotype 2 CHC||SoviHep+ ribavirinb||12 weeks|
|Patients with genotype 3 CHC||SoviHep+ ribavirinb||24 weeks|
Dose reduction of SoviHep is not recommended.
Genotype 1 and 4:
If a patients has a serious adverse reaction potentially related to peginterferon alfa and /or ribavirin, the peginterferon alfa and/or ribavirin dose should be reduced or discontinued. Refer to the peginterferon alfa and ribavirin prescribing information for the additional information about how to reduce and/or discontinue the peginterferon alfa and/or ribavirin dose.
Genotype 2 and 3:
If a patient has a serious adverse reaction potentially related to ribavirin, the ribavirin dose should be modified or discontinued, if appropriate, until the adverse reaction abates or decreases in sverity.Provides guidelines for dose modifications and discontinuation based on the patient’s hemoglobin concentration and cardiac status.
DOSAGES FORMS AND STRENGTHS
Each film coated tablet of SoviHep 400 mg is available as capsules shaped, brick red colored and debossed with 400 on one side and plain on another side.
It is used in combination with ribavirin to peginterferon alfa/ribavirin; the contraindications applicable to those agents are applicable to combination therapies. Refer to the prescribing information of peginterferon alfa and ribavirin for a list of their contraindications.
WARNINGS AND PRECAUTIONS
Pregnancy: Use with Ribavirin or Peginterferon Alfa/Ribavirin
Ribavirin may cause birth defects and /or deaths of the exposed fetus and animal have shown that interferons have abortifacient effects. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin therapy should not be started unless a report of a negative pregnancy test has been obtained immediately prior to initiation of therapy.
When this is used in combinations with ribavirin or peginterferon alfa/ribavirin, women of childbearing potential and their male partners must use two forms of effective contraception during treatment and for at least 6 months after treatment. Monthly pregnancy tests must be performed during this time. There are no data on the effectiveness of systemic hormonal contraceptives in women taking SoviHep therefore, two non-hormonal methods of contraception should be used during treatment with SoviHep and concomitant ribavirin.
The most common adverse events (>=20%) for SoviHep + ribavirin combination therapy were fatigue and headache. The most common adverse events (>=20%) for SoviHep + peginterferon alfa+ ribavirin combination therapy were fatigue, headache, nausea, insomnia and anemia.